Neurology · Connecticut
Neurology studies in Connecticut
63 studies have at least one recruiting site in Connecticut. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
63 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
XingImaging, LLC
- Location
- New Haven, CT
- Eligibility basics
- Ages 40–80
- RecruitingHealthy volunteersEarly Phase 1
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
MODAG GmbH
- Location
- New Haven, CT
- Eligibility basics
- Ages 50–80
- RecruitingHealthy volunteersEarly Phase 1
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers
MODAG GmbH
- Location
- New Haven, CT
- Eligibility basics
- Ages 18–60
- RecruitingHealthy volunteersPhase 1/Phase 2
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Yale University
- Location
- New Haven, CT
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Yale University
- Location
- New Haven, CT
- Eligibility basics
- Ages 18–90
- RecruitingHealthy volunteersEarly Phase 1
Mechanistic Studies of Psilocybin in Headache Disorders
Yale University
- Location
- West Haven, CT
- Eligibility basics
- Ages 21–70
- RecruitingHealthy volunteersEarly Phase 1
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
University of Pennsylvania
- Location
- New Haven, CT + 2 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Farmington, CT + 24 other US sites
- Eligibility basics
- Ages 40–80
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- New Haven, CT + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
AbbVie
- Location
- Stamford, CT + 17 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc
- Location
- New Haven, CT + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Merck Sharp & Dohme LLC
- Location
- New Haven, CT + 34 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Hartford, CT + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Fairfield, CT + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- New Haven, CT + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A/S
- Location
- Stamford, CT + 8 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Farmington, CT + 56 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Waterbury, CT + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
- Location
- New Haven, CT + 13 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S
- Location
- Stamford, CT + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- New Haven, CT + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Stamford, CT + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Stamford, CT + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- New Haven, CT + 52 other US sites
- Eligibility basics
- Ages 50–85
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.